A Salmochelin S4-inspired Ciprofloxacin Trojan Horse Conjugate

Thomas Sanderson, Conor Black, James Southwell, Ellis Wilde, Apurva Pandey, Reyme Herman, Gavin H Thomas, Eszter Boros, Anne Kathrin Duhme-Klair, Anne Routledge

Research output: Contribution to journalArticlepeer-review


A novel ciprofloxacin-siderophore Trojan Horse antimicrobial was prepared by incorporating key design features of salmochelin S4, a stealth siderophore that evades mammalian siderocalin capture via its glycosylated catechol units. As-sessment of the antimicrobial activity of the conjugate revealed that attachment of the salmochelin mimic resulted in decreased potency, compared to ciprofloxacin, against two Escherichia coli strains, K12 and Nissle 1917, in both iron-replete and deplete conditions. This observation could be attributed to a combination of reduced DNA gyrase inhibi-tion, as confirmed by in vitro DNA gyrase assays, and reduced bacterial uptake. Uptake was monitored using radio-labelling with iron-mimetic 67Ga3+, which revealed limited cellular uptake in E. coli K12. In contrast, previously reported staphyloferrin-based conjugates displayed measurable uptake in analogous 67Ga3+, labelling studies. These results suggest that in designing Trojan Horse antimicrobials, the choice of siderophore and the nature and length of the link-er remains a significant challenge.

Original languageEnglish
Pages (from-to)2532–2541
JournalACS Infectious Diseases
Issue number9
Early online date11 Aug 2020
Publication statusPublished - 11 Sept 2020

Bibliographical note

© 2020 American Chemical Society. This is an author-produced version of the published paper. Uploaded in accordance with the publisher’s self-archiving policy. Further copying may not be permitted; contact the publisher for details.

Cite this